Treating Adult Patients of Severe Psoriasis with Methotrexate Leads to Reduction in Biomarkers of Atherosclerosis: A Prospective Study

Overview

Journal Med J Armed Forces India

Specialty General Medicine

Date 2024 Dec 30

PMID 39734852

Authors

Shekhar Neema

Biju Vasudevan

Pratibha Misra

Roma Rai

M K Sibin

Senkadhir Vendhan

Shantanu Banerjee

Vinay Gera

A K Yadav

Affiliations

Soon will be listed here.

Abstract

Background: Psoriasis is a common skin disorder; affecting 0.4-2% of general population and is associated with increased risk of cardiovascular diseases. We conducted this prospective study to determine change in biomarkers of atherosclerosis in plaque psoriasis in patients treated with methotrexate.

Methods: The study was carried out at a tertiary care centre over a period of 1 year after institutional ethical clearance. The study included 50 patients. Adults with severe psoriasis not receiving any systemic treatment for last 3 months were included in the study. Clinical parameters including psoriasis area and severity index (PASI), dermatology quality of life index (DLQI) and estimation of IL-6, hsCRP, and HDL levels and LDL: HDL ratio were done at baseline and at 12 weeks.

Results: A total of 50 patients were included and 42 completed the study. The mean age and mean duration of disease was 44.4 (±13.2) years and 10.8 (±9.9) years, respectively. Pre- and post-treatment mean PASI was 16.3 (±8.3) and 7.43 (±4.9), respectively ( = 0.001). The level of VEGF, IL-6, and hsCRP was 127 (±158) pg/ml, 5.3 (±2.5) pg/ml, and 4.2 (±4.1) mg/L, respectively. The levels of VEGF, IL-6, and hsCRP after 12 weeks of treatment were found to be 59.3 (±61) pg/ml (=0.006), 3.6 (±2.1) pg/ml ( < 0.001), and 2.6 (±3.1) mg/L ( = 0.012), respectively.

Conclusion: Methotrexate use in patients with chronic plaque psoriasis reduces the level of biomarkers of atherosclerosis at 12 weeks. Early treatment with methotrexate may help in reduction of cardiovascular risk in psoriasis patients.

References

Verhoeven F, Prati C, Chouk M, Demougeot C, Wendling D . Methotrexate and cardiovascular risk in rheumatic diseases:A comprehensive review. Expert Rev Clin Pharmacol. 2021; 14(9):1105-1112. DOI: 10.1080/17512433.2021.1932461. View

Elnabawi Y, Dey A, Goyal A, Groenendyk J, Chung J, Belur A . Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. Cardiovasc Res. 2019; 115(4):721-728. PMC: 6432047. DOI: 10.1093/cvr/cvz009. View

Snekvik I, Smith C, Nilsen T, Langan S, Modalsli E, Romundstad P . Obesity, Waist Circumference, Weight Change, and Risk of Incident Psoriasis: Prospective Data from the HUNT Study. J Invest Dermatol. 2017; 137(12):2484-2490. DOI: 10.1016/j.jid.2017.07.822. View

Forkel S, Schon M, Hildmann A, Classen A, John S, Danker K . Inositoylated platelet-activating factor (Ino-C2-PAF) modulates dynamic lymphocyte-endothelial cell interactions and alleviates psoriasis-like skin inflammation in two complementary mouse models. J Invest Dermatol. 2014; 134(10):2510-2520. DOI: 10.1038/jid.2014.170. View

Rifai N . C-reactive protein and coronary heart disease: diagnostic and therapeutic implications for primary prevention. Cardiovasc Toxicol. 2002; 1(2):153-7. DOI: 10.1385/ct:1:2:153. View

Gelfand J, Neimann A, Shin D, Wang X, Margolis D, Troxel A . Risk of myocardial infarction in patients with psoriasis. JAMA. 2006; 296(14):1735-41. DOI: 10.1001/jama.296.14.1735. View

Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P . The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015; 74(3):480-9. PMC: 4345910. DOI: 10.1136/annrheumdis-2014-206624. View

Ridker P, Everett B, Pradhan A, MacFadyen J, Solomon D, Zaharris E . Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N Engl J Med. 2018; 380(8):752-762. PMC: 6587584. DOI: 10.1056/NEJMoa1809798. View

Arnett D, Blumenthal R, Albert M, Buroker A, Goldberger Z, Hahn E . 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019; 140(11):e596-e646. PMC: 7734661. DOI: 10.1161/CIR.0000000000000678. View

10.

Caiazzo G, Fabbrocini G, Di Caprio R, Raimondo A, Scala E, Balato N . Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows. Front Immunol. 2018; 9:1668. PMC: 6099159. DOI: 10.3389/fimmu.2018.01668. View

11.

Dey A, Joshi A, Chaturvedi A, Lerman J, Aberra T, Rodante J . Association Between Skin and Aortic Vascular Inflammation in Patients With Psoriasis: A Case-Cohort Study Using Positron Emission Tomography/Computed Tomography. JAMA Cardiol. 2017; 2(9):1013-1018. PMC: 5815046. DOI: 10.1001/jamacardio.2017.1213. View

12.

Kim-Mitsuyama S, Soejima H, Yasuda O, Node K, Jinnouchi H, Yamamoto E . Reduction in hsCRP levels is associated with decreased incidence of cardiovascular events in Japanese hypertensive women but not in men. Sci Rep. 2020; 10(1):17040. PMC: 7550334. DOI: 10.1038/s41598-020-73905-4. View

13.

McDonald C, Calabresi P . Psoriasis and occlusive vascular disease. Br J Dermatol. 1978; 99(5):469-75. DOI: 10.1111/j.1365-2133.1978.tb02012.x. View

14.

Ahlehoff O, Gislason G, Charlot M, Jorgensen C, Lindhardsen J, Olesen J . Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med. 2010; 270(2):147-57. DOI: 10.1111/j.1365-2796.2010.02310.x. View

15.

Elmets C, Leonardi C, Davis D, Gelfand J, Lichten J, Mehta N . Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019; 80(4):1073-1113. DOI: 10.1016/j.jaad.2018.11.058. View

16.

Taleb S, Tedgui A . IL-17 in atherosclerosis: the good and the bad. Cardiovasc Res. 2017; 114(1):7-9. DOI: 10.1093/cvr/cvx225. View

17.

El-Mongy S, Fathy H, Abdelaziz A, Omran E, George S, Neseem N . Subclinical atherosclerosis in patients with chronic psoriasis: a potential association. J Eur Acad Dermatol Venereol. 2009; 24(6):661-6. DOI: 10.1111/j.1468-3083.2009.03481.x. View

18.

Wu J, Poon K, Channual J, Shen A . Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012; 148(11):1244-50. DOI: 10.1001/archdermatol.2012.2502. View

19.

Mehta N, Yu Y, Pinnelas R, Krishnamoorthy P, Shin D, Troxel A . Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med. 2011; 124(8):775.e1-6. PMC: 3146037. DOI: 10.1016/j.amjmed.2011.03.028. View

20.

Egeberg A, Skov L, Joshi A, Mallbris L, Gislason G, Wu J . The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events. J Am Acad Dermatol. 2017; 77(4):650-656.e3. PMC: 5657544. DOI: 10.1016/j.jaad.2017.06.028. View